posted May 06, 2022 04:52 pm by carolinegan
(7)
https://themarketherald.ca/medicenna-announces-new-clinical-data-showing-dose-dependent-stimulation-of-anti-cancer-immune-cells-with-mdna11-in-the-phase-1-2-ability-study-2022-05-02/
rate and reply
posted January 26, 2022 02:24 pm by windymayor1
(29)
Good News. Not sure what the market is waiting for ?!
rate and reply
posted January 26, 2022 08:55 am by Betteryear2
(3277)
MDNA11 demonstrates a 30-fold increase in affinity for IL-2 receptor beta without binding to IL-2 receptor alpha when compared to recombinant human IL-2 -- MDNA11 was well-tolerated and induced
...read more
posted November 17, 2021 08:04 am by HarryGluten
(0)
$mdna 52 week high of $6.82. If it was done once, it can be done again, esp with big catalyst in less than one month!
rate and reply
posted November 17, 2021 06:45 am by HarryGluten
(0)
This would be huge: Resesarch Capital Analyst Uddin believes efforts to secure deal for $MDNA 55 prior to start of Phase 3 clinical trial will serve as key catalyst, as he made the assumption of a
...read more
posted November 17, 2021 06:42 am by HarryGluten
(0)
$mdna Canadian biotech company Medicenna Therapeutics (Medicenna Therapeutics Stock Quote, Chart, News TSX:MDNA) has lost a lot of ground in 2021 but analyst Andre Uddin of Research Capital
...read more
posted November 16, 2021 10:51 am by HarryGluten
(0)
$mdna big swing trading play... mdna will report data on their lead drug program (mdna 11) in December 2022! Stock will continue to rally into December, and if results are good, I agree with zack'
...read more
posted November 16, 2021 07:20 am by HarryGluten
(0)
$mdna third clinical site for mdna 11 is now recruiting in Victoria, Australia https://clinicaltrials.gov/ct2/show/NCT05086692#contacts
rate and reply
posted November 15, 2021 10:33 am by HarryGluten
(0)
$mdna at Stifel conference presentation - Expect to present mdna 11 efficacy data at ASCO June 3, 2022 - MDNA 55 discussions still active and ongoing with several
...read more
posted November 13, 2021 07:01 am by HarryGluten
(0)
$mdna December setting up to be huge month of catalysts! Pivotal month. PK/PD for mdna 11 in late December. Assuming that goes well, we will be off to the races as investors build positions for 2022.
...read more
posted November 13, 2021 07:00 am by HarryGluten
(0)
Good seeking alpha article summarzing $MDNA opportunity... end of 2021 and year 2022 looking very good for this little stock that could...multi-bagger potential within a year... good time to buy
...read more
posted November 13, 2021 07:00 am by HarryGluten
(0)
$MDNA CEO Merchant bought $100K of shares open market recently, avg price $2.15. CFO added a few shares too. Merchant already largest shareholder at 30%+,continues toadd. This is very positive given 9
...read more
posted November 06, 2021 10:02 am by HarryGluten
(0)
According to Canaccord : in last 5 years, stocks on TSX down more than 15% ytd as of mid-Nov have underperformed the index by almost 4% over the month to mid-Dec and then, in the subsequent month (mid
...read more
posted November 05, 2021 10:37 am by HarryGluten
(0)
nktr reported earnings yesterday. Stock down 20%+ as market not liking some early data results from ph1/ph2 keytruda combo + their main drug IL-2 BEMPEG NKTR 214 for lung cancer (propel); recall that
...read more
posted October 28, 2021 07:33 am by HarryGluten
(0)
$mdna Updated: 10/27/2021 3 additional sites have been added in Australia. Can go to clinical .gov site Medicenna ability study https://clinicaltrials.gov/ct2/show
...read more
posted October 07, 2021 07:31 am by HarryGluten
(0)
Publication of $MDNA 11 (IL-2) animal studies, incl non-human primates in the prestigious peer-revieed ASCO today. Title: $MDNA 11 is a long-acting IL-2 superkine that potentiates durable immune
...read more
posted October 05, 2021 08:46 am by HarryGluten
(0)
Not crappin on $nktr, $nltx thor and other il2 players. cancer immuno mkt is huge, there'll be many winners in space not just one. $mdna at $160 mm mkt is the cheapest il2 player with the greatest
...read more
posted October 04, 2021 10:16 am by HarryGluten
(0)
$mdna We know how $nktr and thor did in their ph1-2 trials. They both showed NO monotheraphy efficacy. That's why they are in phase 3 combo trials with checkpoint inhibitors.
...read more
posted October 01, 2021 09:35 am by HarryGluten
(0)
$mdna October is upon us! We are about two months away from mdna reporting preliminary topline results for potential blockbuster mdna 11. Expect a steady run-up to December, and when mdna shows it'
...read more
posted July 01, 2021 03:48 pm by juniorbullalive
(7778)
I would say the stock is telling you the franchise drug does not have the needed efficacy to be commercially vuable -do some due dilly for heavens sake -look for the clues
rate and reply